Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 3/20 | 0.60 |
| ▸ | GRM5 | P41594 | 3/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.46 |
| ▸ | PRKDC | P78527 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19672815 | 0.86 | ATR (0.57) | ATRGRM5PIK3CDPIK3CAPIK3CG | |
| SCHEMBL3461940 | 0.84 | PIK3CD (0.59) | ATRPIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL506051 | 0.84 | ATR (0.62) | ATRGRM5PIK3CDPRKDCATM | |
| SCHEMBL10255502 | 0.84 | PIK3CD (0.49) | ATRGRM5PIK3CDPIK3CAPIK3CG | |
| SCHEMBL13138607 | 0.82 | GRM5 (0.60) | ATRGRM5PIK3CDPIK3CAPIK3CG | |
| SCHEMBL17434318 | 0.81 | ATR (0.56) | ATRGRM5PIK3CDPRKDCPIM1 | |
| SCHEMBL17204310 | 0.81 | ATR (0.56) | ATRGRM5PIK3CDPRKDCATM | |
| SCHEMBL3837215 | 0.81 | ATR (0.41) | ATRGRM5PIK3CDPIK3CAPIK3CG | |
| SCHEMBL261742 | 0.80 | ATR (0.54) | ATRGRM5PRKDCPIM1PIM3 | |
| SCHEMBL30050535 | 0.80 | ATR (0.54) | ATRGRM5PRKDCPIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590064-B2 | Substituted benzamides for inhibiting perk activity | ELI LILLY AND COMPANY (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4039675-B1 | PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS | LILLY CO ELI (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-117510405-A | Phenyl-2-hydroxy-acetamido-2-methyl-phenyl compounds | 礼来公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230373922-A1 | PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS FOR THE TREATMENT OF PANCREATIC CANCER | LILLY CO ELI (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373922-A1 | PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS FOR THE TREATMENT OF PANCREATIC CANCER | LILLY CO ELI (US) | 2023-11-23 | — | — | US | disclosed |
| CN-110831927-B | Phenyl-2-hydroxy-acetamido-2-methyl-phenyl compounds | 礼来公司 | 2023-07-14 | — | — | CN | disclosed |
| US-11655214-B2 | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds for the treatment of pancreatic cancer | ELI LILLY AND COMPANY (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655214-B2 | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds for the treatment of pancreatic cancer | ELI LILLY AND COMPANY (US) | 2023-05-23 | — | — | US | disclosed |
| EP-4039675-A1 | PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS | Eli Lilly and Company (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-3612519-B1 | PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS | LILLY CO ELI (US) | 2021-12-01 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7674791-B2 | Triazolopyrazines and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1501514-A4 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20070010520-A1 | Triazolopyrazines and methods of making and using the same | BIOGEN IDEC MA INC. | 2007-01-11 | — | — | US | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1615931-A1 | TRIAZOLOPYRAZINES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1501514-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004092177-A1 | TRIAZOLOPYRAZINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2003093297-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | ATR 556/4885GRM5 327/4885PIK3CD 375/4885 |
| US-11655214-B2 | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds for the treatment of pancreatic cancer | PNLIP, RNASE1, AMY2A | ATR 1953/4885GRM5 2244/4885PIK3CD 1414/4885 |
| US-20230373922-A1 | PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS FOR THE TREATMENT OF PANCREATIC CANCER | PNLIP, RNASE1, AMY2A | ATR 1804/4885GRM5 1762/4885PIK3CD 1301/4885 |
| US-20070010520-A1 | Triazolopyrazines and methods of making and using the same | ADORA2A, ADORA3, ADORA1 | ATR 1363/4885GRM5 95/4885PIK3CD 1477/4885 |
| US-12590064-B2 | Substituted benzamides for inhibiting perk activity | EIF2AK3, EIF2AK1, EIF2AK4 | ATR 1220/4885GRM5 4507/4885PIK3CD 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.